Sinntaxis
Private Company
Funding information not available
Overview
Sinntaxis is a private, preclinical-stage biotech company targeting the significant unmet need for post-stroke recovery therapies. Its core technology involves inhibiting mGluR5 to beneficially remodel brain connectivity and enhance functional recovery, even when treatment begins days after the stroke event. The company has filed foundational IP, secured non-dilutive grant funding, and entered a strategic collaboration with Addex Therapeutics to advance dipraglurant, a phase II-ready candidate, for brain injury recovery.
Technology Platform
Preclinical discovery platform focused on mGluR5 negative allosteric modulators (NAMs) to enhance synaptic remodeling and functional recovery after stroke, with treatment effective even when initiated days after the event.
Opportunities
Risk Factors
Competitive Landscape
The competitive landscape for post-stroke recovery drugs is relatively sparse with no approved pharmacotherapies, placing Sinntaxis in a potential first-mover position. However, several companies and academic groups are investigating various mechanisms (e.g., growth factors, cell therapies, other neuromodulators) for neuro-repair, and large pharma may enter if the concept is validated.